Entorhinal cortex layer III neurons represent a critical node in the hippocampal memory circuit and are among the first neuronal populations affected in Alzheimer's disease (AD). These glutamatergic projection neurons provide the primary gateway through which cortical information flows into the hippocampus, making them essential for memory formation and consolidation. The selective vulnerability of layer III neurons to tau pathology has made them a focal point for understanding the early pathogenesis of AD and developing therapeutic interventions[1][2].
The entorhinal cortex serves as the interface between the neocortex and the hippocampal formation, integrating multimodal cortical inputs and transmitting them to hippocampal subregions. Layer III specifically projects to the CA1 pyramidal cell layer and subiculum via the temporoammonic (TA) pathway, also known as the direct perforant path. This direct projection bypasses the dentate gyrus and CA3, providing a fast, dedicated channel for cortical information that is particularly important for episodic memory retrieval[3].
The entorhinal cortex is located in the medial temporal lobe, forming the most caudal portion of the parahippocampal gyrus. It is divided into medial and lateral entorhinal areas, with layer III neurons exhibiting distinct morphological and electrophysiological properties. These neurons are primarily pyramidal cells with medium-sized somata, extending apical dendrites into layer I and basal dendrites into layer IV[1:1].
Layer III neurons are characterized by their regular spiking phenotype and robust dendritic architecture. They express specific molecular markers including reelin and WFS1 (wolframin), which help distinguish them from layer II neurons that project to the dentate gyrus[4]. Theaxonal projections of layer III neurons form the temporoammonic pathway, which terminates in the stratum lacunosum-moleculare of CA1 and the molecular layer of the subiculum.
The temporoammonic (TA) pathway constitutes one of three major projections from the entorhinal cortex to the hippocampus. Unlike the perforant path (from layers II/III to dentate gyrus and CA3), the TA pathway provides a direct monosynaptic connection from layer III to CA1 pyramidal cells. This direct pathway is crucial for:
The TA pathway terminates specifically in the stratum lacunosum-moleculare of CA1, where it receives inhibitory modulation from local interneurons. This precise termination pattern allows for targeted regulation of CA1 neuronal activity during memory processes[3:1][2:1].
Entorhinal layer III neurons are essential for episodic memory formation and retrieval. The entorhinal-hippocampal circuit processes information about events, locations, and temporal sequences that define autobiographical memories. Layer III neurons integrate inputs from multiple cortical association areas, including:
This integration allows layer III neurons to construct comprehensive representations of episodic experiences that are then transmitted to CA1 for pattern separation and completion[2:2][5].
The medial entorhinal cortex, where layer III neurons are abundant, contains grid cells that provide spatial navigation signals. These neurons fire at the vertices of a hexagonal grid pattern covering the environment. Layer III neurons receive grid cell input and relay this spatial information to CA1, supporting path integration and navigation-based memory formation[5:1].
Entorhinal cortex layer III neurons are among the first to accumulate hyperphosphorylated tau protein in Alzheimer's disease. Neurofibrillary tangles (NFTs) in layer III appear before the classic amyloid plaque formation and represent a primary driver of neuronal dysfunction[6]. Key pathological features include:
The accumulation of tau in entorhinal neurons follows a predictable staging pattern, with layer III affected early in the disease course. This early involvement explains why memory deficits appear before significant amyloid burden in many patients[7][8].
Tau pathology in layer III neurons disrupts the temporoammonic pathway, leading to downstream effects in CA1. The consequences include:
Studies in 3xTg-AD mouse models demonstrate progressive excitability changes in layer III neurons, with hyperexcitability preceding overt pathology. This early dysfunction provides a therapeutic window for intervention[9][10].
Imaging studies reveal significant structural alterations in the entorhinal cortex during early AD:
These structural changes parallel the accumulation of tau and reflect both neuronal loss and atrophy of remaining neurons[11][12].
The pathological cascade in layer III neurons involves multiple phosphorylation sites on tau protein. Key mechanisms include:
The propagation of tau along entorhinal-hippocampal circuits follows connectivity patterns, with TA pathway neurons spreading pathology to CA1 and subiculum[13].
Before overt neuronal loss, layer III neurons exhibit synaptic alterations:
These synaptic changes correlate with cognitive deficits and represent therapeutic targets[14].
Microglial activation in the entorhinal cortex accompanies early tau pathology:
Microglial activation represents both a consequence of tau pathology and a contributor to disease progression through neuroinflammation[15].
Entorhinal cortex layer III dysfunction correlates with specific cognitive domains:
Longitudinal studies demonstrate that tau accumulation in the entorhinal cortex precedes and predicts memory decline by years, making it a critical biomarker for disease progression[16][17].
The entorhinal cortex serves as a key region for AD biomarker development:
These biomarkers enable detection of pathological changes before clinical symptoms emerge, facilitating early intervention[18].
An emerging area of research links olfactory dysfunction to entorhinal pathology:
Understanding these connections may lead to novel therapeutic approaches targeting early tau propagation[19][20].
The vulnerability of layer III neurons provides therapeutic opportunities:
Clinical trials are evaluating these approaches in subjects with early AD or preclinical changes[6:1].
Restoring temporoammonic pathway function represents a novel strategy:
Computational modeling suggests that restoring layer III input to CA1 could significantly improve memory performance in early AD[21].
Protecting layer III neurons from tau-induced dysfunction:
These neuroprotective approaches may preserve cognitive function when initiated early in the disease course[22].
Several mouse models recapitulate layer III pathology:
These models enable mechanistic studies and therapeutic testing[9:1][10:1].
In vivo recordings from layer III neurons reveal:
These electrophysiological changes provide functional readouts for therapeutic efficacy.
Future research focuses on:
Ongoing efforts aim to:
Clinical trials in preclinical populations will test:
Entorhinal cortex layer III neurons represent a critical node in the hippocampal memory circuit and are among the first casualties of Alzheimer's disease pathology. Their position as the primary source of cortical input to CA1 makes them essential for episodic memory function. The early accumulation of tau in these neurons, reflected in neurofibrillary tangle formation and subsequent temporoammonic pathway dysfunction, explains the characteristic memory deficits that herald AD onset.
Understanding the molecular mechanisms underlying layer III vulnerability, including tau phosphorylation, synaptic dysfunction, and microglial activation, provides therapeutic targets for disease modification. The ongoing development of biomarkers targeting entorhinal pathology enables earlier diagnosis and intervention. Future therapeutic strategies will focus on protecting layer III neurons, restoring temporoammonic pathway function, and ultimately preventing tau accumulation in this critical memory circuit node.
Witter MP, Wouterlood FG, Naber PA, Van Haeften T. The entorhinal cortex: organization, subcortical connections and cortical interactions. Anatomical Embryology. 2000. ↩︎ ↩︎
Van Strien NM, Cappaert NL, Witter MP. The anatomy of memory: an interactive overview of the parahippocampal-hippocampal network. Nature Reviews Neuroscience. 2009. ↩︎ ↩︎ ↩︎
Hammond RS, et al. Temporoammonic pathway input to hippocampal CA1 neurons. Hippocampus. 2007. ↩︎ ↩︎
Klausberger T, et al. Brain-state- and cell-type-specific firing of hippocampal interneurons in vivo. Nature. 2003. ↩︎
Strange BA, et al. The entorhinal cortex: functional organization and Alzheimer's disease. Nature Reviews Neurology. 2019. ↩︎ ↩︎
Hardenberg T, et al. Early tau pathology in the entorhinal cortex of Alzheimer's disease patients. Acta Neuropathologica. 2023. ↩︎ ↩︎
Griffiths J, et al. Tau propagation from the entorhinal cortex to the hippocampus. Journal of Neuroscience. 2022. ↩︎
Mattsson N, et al. Tau and neurodegeneration in the entorhinal cortex. JAMA Neurology. 2018. ↩︎
Fu Z, Caples R, Zeldovich M, et al. Layer-specific firing alterations in the entorhinal cortex of the 3xTg-AD mouse model. Neurobiology of Aging. 2021. ↩︎ ↩︎
Hernandez ML, et al. Entorhinal cortex hyperexcitability in mouse models of AD. Nature Communications. 2022. ↩︎ ↩︎
Bilgel M, et al. Tau and beta-amyloid accumulation in the entorhinal cortex. Neurobiology of Aging. 2016. ↩︎
Pruessner M, et al. Entorhinal cortex thinning in preclinical Alzheimer's disease. Hippocampus. 2020. ↩︎
Ganguly G, et al. Tau release from neurons via extracellular vesicles. Acta Neuropathologica. 2021. ↩︎
Kelley R, et al. Synaptic changes in the entorhinal cortex in early AD. Acta Neuropathologica Communications. 2019. ↩︎
Defawe R, et al. Microglial activation in entorhinal cortex during early AD. Glia. 2024. ↩︎
Hanseeuw BJ, et al. Tau accumulation in entorhinal cortex predicts memory decline. Neurology. 2019. ↩︎
Chen X, et al. Entorhinal cortex dysfunction in early Alzheimer's disease. Brain. 2024. ↩︎
Agosta F, et al. Structural and functional brain changes in early-onset Alzheimer's disease. Neurology. 2019. ↩︎
Vassilev C, et al. Olfactory dysfunction as an early marker for tauopathy. Alzheimer's & Dementia. 2023. ↩︎
Oh J, et al. Tau pathology in the olfactory bulb correlates with cognitive impairment. Journal of Alzheimer's Disease. 2015. ↩︎
Morado-John A, et al. Computational modeling of entorhinal-hippocampal circuit dysfunction in AD. Cell Reports. 2023. ↩︎
Liu L, et al. The role of the entorhinal cortex in Alzheimer's disease progression. Frontiers in Neuroscience. 2019. ↩︎